---
figid: PMC7913382__jcm-10-00566-g005
figtitle: Mitogen-activated protein kinase (MAPK)/ extracellular signal-regulated
  kinase (ERK) pathway crosstalk, downstream effects, and inhibitors currently being
  trialled in pancreatic cancer treatment
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC7913382
filename: jcm-10-00566-g005.jpg
figlink: pmc/articles/PMC7913382/figure/jcm-10-00566-f005/
number: F5
caption: Mitogen-activated protein kinase (MAPK)/ extracellular signal-regulated kinase
  (ERK) pathway crosstalk, downstream effects, and inhibitors currently being trialled
  in pancreatic cancer treatment.
papertitle: The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic
  Cancer Therapies.
reftext: Andres Garcia-Sampedro, et al. J Clin Med. 2021 Feb;10(4):566.
year: '2021'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9576415
figid_alias: PMC7913382__F5
figtype: Figure
redirect_from: /figures/PMC7913382__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7913382__jcm-10-00566-g005.html
  '@type': Dataset
  description: Mitogen-activated protein kinase (MAPK)/ extracellular signal-regulated
    kinase (ERK) pathway crosstalk, downstream effects, and inhibitors currently being
    trialled in pancreatic cancer treatment.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGF
  - EGFR
  - GRB2
  - STAT3
  - XYLT2
  - SOS1
  - SOS2
  - AMELX
  - KRAS
  - NRAS
  - YAP1
  - TAFAZZIN
  - WWTR1
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MAPK3
  - MAPK1
  - AMG
  - Encorafenib
  - Dabrafenib
  - Cobimetinib
  - Selumetinib
  - Binimetinib
  - Trametinib
  - inflammation
---
